Numero della rivista 26 2024

Realtà Virtuale e psichedelia: le potenzialità delle esperienze tecnodeliche alla conquista della mente

• Scritto da Fabrizio Serrao & Alessandro Gabbiadini

Marshall, P. (2005). “Mind beyond the brain: reducing valves and metaphysics,” in Mystical Encounters with the Natural World, (Oxford: Oxford University Press).

Martial, C., Cassol, H., Slater, M., Bourdin, P., Mensen, A., Oliva, R., ... & Núñez, P. (2023). Electroencephalographic signature of out-of-body experiences induced by virtual reality: A novel methodological approach. Journal of Cognitive Neuroscience, 35(9), 1410-1422.

Martinotti, G., Santacroce, R., Pettorruso, M., Montemitro, C., Spano, M. C., Lorusso, M., ... & Lerner, A. G. (2018). Hallucinogen persisting perception disorder: etiology, clinical features, and therapeutic perspectives. Brain Sciences, 8(3), 47.

Mayer, A., Schwiedrzik, C. M., Wibral, M., Singer, W., & Melloni, L. (2015). Expecting to see a letter: alpha oscillations as carriers of top-down sensory predictions. Cerebral Cortex, 26(7), 3146-3160.

Naranjo, C. (1974). The Healing Journey. 1974. 

Nichols, D. E. (2004). Hallucinogens. Pharmacology & therapeutics, 101(2), 131-181.

Nutt, D., King, L. A., Saulsbury, W., & Blakemore, C. (2007). Development of a rational scale to assess the harm of drugs of potential misuse. the Lancet, 369(9566), 1047-1053.

Osmond, H. (1957). A review of the clinical effects of psychotomimetic agents. Annals of the New York academy of sciences, 66(3), 418-434.

Rastelli, C., Greco, A., Kenett, Y. N., Finocchiaro, C., & De Pisapia, N. (2022). Simulated visual hallucinations in virtual reality enhance cognitive flexibility. Scientific reports, 12(1), 4027.

Sessa, B. (2008). Is it time to revisit the role of psychedelic drugs in enhancing human creativity?. Journal of psychopharmacology, 22(8), 821-827.

Sessa, B. (2017). MDMA and PTSD treatment:“PTSD: from novel pathophysiology to innovative therapeutics”. Neuroscience letters, 649, 176-180.

Sessa, B., Higbed, L., & Nutt, D. (2019). A review of 3, 4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy. Frontiers in psychiatry, 10, 138.

Shulgin, A. T., & Shulgin, A. (1991). PIHKAL: a chemical love story (Vol. 963009605). Berkeley, CA: Transform Press.

Spitzer, M., Thimm, M., Hermle, L., Holzmann, P., Kovar, K. A., Heimann, H., ... & Schneider, F. (1996). Increased activation of indirect semantic associations under psilocybin. Biological psychiatry, 39(12), 1055-1057.

Sterzer, P., Adams, R. A., Fletcher, P., Frith, C., Lawrie, S. M., Muckli, L., ... & Corlett, P. R. (2018). The predictive coding account of psychosis. Biological psychiatry, 84(9), 634-643.

Suzuki, K., Roseboom, W., Schwartzman, D. J., & Seth, A. K. (2017). A deep-dream virtual reality platform for studying altered perceptual phenomenology. Scientific reports, 7(1), 15982.

Swanson, L. R. (2018). Unifying theories of psychedelic drug effects. Frontiers in pharmacology, 9, 344412.

Timmermann, C., Roseman, L., Schartner, M., Milliere, R., Williams, L. T., Erritzoe, D., ... & Carhart-Harris, R. L. (2019). Neural correlates of the DMT experience assessed with multivariate EEG. Scientific reports, 9(1), 16324.

Torrance, E. P. (1966). Torrance tests of creative thinking. Educational and Psychological Measurement.

Treleaven, J., Battershill, J., Cole, D., Fadelli, C., Freestone, S., Lang, K., & Sarig-Bahat, H. (2015). Simulator sickness incidence and susceptibility during neck motion-controlled virtual reality tasks. Virtual Reality, 19, 267-275.

Yaden, D. B., Yaden, M. E., & Griffiths, R. R. (2021). Psychedelics in psychiatry—keeping the renaissance from going off the rails. JAMA psychiatry, 78(5), 469-470.